Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L R Kelland

Showing results (1-10 of 148) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 4, 2004
Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug developmentL R Kelland
Journal of Inorganic Biochemistry|January 8, 2000
Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer ChemotherapyL R Kelland
Expert Opinion on Investigational Drugs|November 28, 2000
Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current statusL R Kelland
Drugs|June 23, 2000
Preclinical perspectives on platinum resistanceL R Kelland
Idrugs : the Investigational Drugs Journal|August 30, 2005
Small molecule anticancer drugsL R Kelland
The Lancet. Oncology|March 22, 2002
Telomerase: biology and phase I trialsL R Kelland
Expert Opinion on Investigational Drugs|November 4, 2000
An update on satraplatin: the first orally available platinum anticancer drugL R Kelland
Critical Reviews in Oncology/Hematology|December 1, 1993
New platinum antitumor complexesL R Kelland
Anti-Cancer Drugs|October 19, 2000
Telomerase inhibitors: targeting the vulnerable end of cancer?L R Kelland
Cancer Chemotherapy and Pharmacology|January 1, 1992
Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell linesL R Kelland, G Abel
Pageof 15

Showing results (1-10 of 148) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|May 4, 2004
Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug developmentL R Kelland
Journal of Inorganic Biochemistry|January 8, 2000
Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer ChemotherapyL R Kelland
Expert Opinion on Investigational Drugs|November 28, 2000
Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current statusL R Kelland
Drugs|June 23, 2000
Preclinical perspectives on platinum resistanceL R Kelland
Idrugs : the Investigational Drugs Journal|August 30, 2005
Small molecule anticancer drugsL R Kelland
The Lancet. Oncology|March 22, 2002
Telomerase: biology and phase I trialsL R Kelland
Expert Opinion on Investigational Drugs|November 4, 2000
An update on satraplatin: the first orally available platinum anticancer drugL R Kelland
Critical Reviews in Oncology/Hematology|December 1, 1993
New platinum antitumor complexesL R Kelland
Anti-Cancer Drugs|October 19, 2000
Telomerase inhibitors: targeting the vulnerable end of cancer?L R Kelland
Cancer Chemotherapy and Pharmacology|January 1, 1992
Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell linesL R Kelland, G Abel
Pageof 15